(Q33181373)

23 July 2017

Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins (English)

1 reference

23 July 2017

cardiovascular disease

1 reference

0 references

Rauch U

1

1 reference

23 July 2017

Osende JI

2

1 reference

23 July 2017

Chesebro JH

3

1 reference

23 July 2017

Fuster V

4

1 reference

23 July 2017

Vorchheimer DA

5

1 reference

23 July 2017

Harris K

6

1 reference

23 July 2017

Harris P

7

1 reference

23 July 2017

Sandler DA

8

1 reference

23 July 2017

Fallon JT

9

1 reference

23 July 2017

Jayaraman S

10

1 reference

23 July 2017

Badimon JJ

11

1 reference

23 July 2017

1 November 2000

1 reference

23 July 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Atherosclerosis

1 reference

23 July 2017

153

1 reference

23 July 2017

1

1 reference

23 July 2017

181-189

1 reference

New views on the relationship of plasma lipids to cardiovascular disease

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Cholesterol lowering and coronary artery disease: mechanisms of risk reduction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Cholesterol management in theory and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Platelet function in hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Human type II hyperlipoproteinemia enhances platelet-collagen adhesion in flowing nonanticoagulated blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Increased thromboxane biosynthesis in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

In vivo evaluation of microcirculation by coherent light scattering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Coronary plaque disruption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Coronary risk factors and plaque morphology in men with coronary disease who died suddenly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

Statins do more than just lower cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

New insights into plaque stabilisation by lipid lowering.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900397-X

10.1016/S0021-9150(00)00397-X

7 January 2021

Identifiers

DOI

1 reference

23 July 2017

1 reference